Anticoagulant Rodenticides
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Toxicological Reviews
- Vol. 24 (4), 259-269
- https://doi.org/10.2165/00139709-200524040-00005
Abstract
Anticoagulant pesticides are used widely in agricultural and urban rodent control. The emergence of warfarin-resistant strains of rats led to the introduction of a new group of anticoagulant rodenticides variously referred to as ‘superwarfarins’, ‘single dose’ or ‘long-acting’. This group includes the second generation 4-hydroxycoumarins brodifacoum, bromadiolone, difenacoum, flocoumafen and the indanedione derivatives chlorophacinone and diphacinone. Most cases of anticoagulant rodenticide exposure involve young children and, as a consequence, the amounts ingested are almost invariably small. In contrast, intentional ingestion of large quantities of long-acting anticoagulant rodenticides may cause anticoagulation for several weeks or months. Occupational exposure has also been reported. Anticoagulant rodenticides inhibit vitamin K1-2,3 epoxide reductase and thus the synthesis of vitamin K and subsequently clotting factors II, VII, IX and X. The greater potency and duration of action of long-acting anticoagulant rodenticides is attributed to their: (i) greater affinity for vitamin K1-2,3-epoxide reductase; (ii) ability to disrupt the vitamin K1-epoxide cycle at more than one point; (iii) hepatic accumulation; and (iv) unusually long biological half-lives due to high lipid solubility and enterohepatic circulation. Substantial ingestion produces epistaxis, gingival bleeding, widespread bruising, haematomas, haematuria with flank pain, menorrhagia, gastrointestinal bleeding, rectal bleeding and haemorrhage into any internal organ; anaemia may result. Spontaneous haemoperitoneum has been described. Severe blood loss may result in hypovolaemic shock, coma and death. The first clinical signs of bleeding may be delayed and patients may remain anticoagulated for several days (warfarin) or days, weeks or months (long-acting anticoagulants) after ingestion of large amounts. There are now sufficient data in young children exposed to anticoagulant rodenticides to conclude that routine measurement of the international normalised ratio (INR) is unnecessary. In all other cases, the INR should be measured 36–48 hours post exposure. If the INR is normal at this time, even in the case of long-acting formulations, no further action is required. If active bleeding occurs, prothrombin complex concentrate (which contains factors II, VII, IX and X) 50 units/kg, or recombinant activated factor VII 1.2–4.8mg or fresh frozen plasma 15 mL/kg (if no concentrate is available) and phytomenadione 10mg intravenously (100 µg/kg bodyweight for a child) should be given. If there is no active bleeding and the INR is ≤4.0, no treatment is required; if the INR is ≥4.0 phytomenadione 10mg should be administered intravenously.Keywords
This publication has 74 references indexed in Scilit:
- Haemorrhagic Diathesis Due to Criminal Poisoning with WarfarinActa Medica Scandinavica, 2009
- Recombinant Factor VIIa for Rapid Reversal of Warfarin Anticoagulation in Acute Intracranial HemorrhageMayo Clinic Proceedings, 2004
- 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance SystemThe American Journal of Emergency Medicine, 2000
- Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulationThe American Journal of Cardiology, 1999
- Superwarfarin ToxicityClinical Journal of Sport Medicine, 1998
- Spontaneous hemorrhage associated with accidental brodifacoum poisoning in a childThe Journal of Pediatrics, 1993
- Fatal rodenticide poisoning with brodifacoumAnnals of Emergency Medicine, 1992
- EPIDEMIC OF HAEMORRHAGIC DISEASE IN VIETNAMESE INFANTS CAUSED BY WARFARIN-CONTAMINATED TALCSThe Lancet, 1983
- Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in manJournal of Pharmacy and Pharmacology, 1973
- STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN*JCI Insight, 1963